rilpivirine
Selected indexed studies
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (N Engl J Med, 2020) [PMID:32130806]
- Dolutegravir-rilpivirine coformulation. (Curr Opin HIV AIDS, 2018) [PMID:29553948]
- Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. (Expert Rev Anti Infect Ther, 2022) [PMID:35596583]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Cabotegravir Plus Rilpivirine: First Approval. (2020) pubmed
- Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. (2022) pubmed
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (2020) pubmed
- Dolutegravir-rilpivirine coformulation. (2018) pubmed
- Dolutegravir/Rilpivirine: A Review in HIV-1 Infection. (2018) pubmed
- Rilpivirine. (2012) pubmed
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. (2021) pubmed
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. (2021) pubmed
- Rilpivirine: The Key for Long-term Success. (2017) pubmed
- Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology. (2023) pubmed